ResMed Inc. (RMD)

ResMed beat expectations on both the top and bottom line in its fiscal fourth quarter of 2026, reported August 6, 2026, as revenue rose about 9% to roughly $1.5 billion and adjusted EPS came in at $2.95. The $2.95 per share result topped the $2.89 estimate by 2.1%, while revenue of about $1.5 billion edged the $1.46 billion consensus by 0.2%; net income increased about 1% to roughly $383 million from $379.7 million a year ago, and EPS was up about 16% from $2.55. Profitability held at a high level, with gross margin near 58% and operating margin about 31%, alongside gross profit of roughly $855 million and operating income of about $449 million. Cash generation remained sizable, with operating cash flow of about $1.8 billion, and the company returned capital through roughly $700 million of share repurchases and about $350 million in dividends. Consensus for the next period calls for EPS of $2.85 on revenue of $1.42 billion.